Captozyme Inc., a Gainesville, Fla.-based biotechnology company focused on therapeutic enzyme-based products for health and wellness, raised $3.4m in Series A funding.
Backers were not disclosed.
The company intends to use the funds to manufacture and launch its main product.
Led by Aaron Cowley, PhD, Co-founder, Captozyme is advancing Nephure™, an oxalate-degrading enzyme that facilitates a low-oxalate diet.
The company, which plans to launch Nephure in the spring of 2017, is a resident of the Sid Martin Biotechnology Institute at the University of Florida.
FinSMEs
16/03/2017